Navigation Links
Discovery Labs Presents Surfaxin and Aerosurf Data At the Pediatric,Academic Societies' Annual Meeting

upplemental oxygen, which increases their risk of developing BPD. Discovery believes that after an initial RDS treatment, BPD may be successfully treated with repeated doses of a non-immunogenic, precision-engineered synthetic surfactant (Surfaxin) to improve the clinical outcome of these infants.

Discovery's Proprietary KL-4 Surfactant Technology: Product Candidates Surfaxin(r) and Aerosurf(tm)

Discovery's surfactant product candidates, including Surfaxin and Aerosurf, are engineered versions of natural human lung surfactant and contain the precision-engineered KL-4 peptide. KL-4 is a 21 amino acid protein-like substance that is designed to closely mimic the essential attributes of human surfactant protein B (SP-B), the surfactant protein most important for the proper functioning of the respiratory system. KL-4 surfactant has the potential to be precisely formulated, either as a liquid instillate, aerosolized liquid or dry powder, to address various respiratory diseases affecting premature infants, children and adults.

Surfaxin, a precision-engineered Surfactant Replacement Therapy (SRT) administered as a liquid-instillate, represents a potential alternative to animal-derived surfactants. Surfaxin's precision-engineered and non-immunogenic nature allows it to be further developed as a therapeutic to address other pulmonary conditions in neonatal and pediatric medicine. Data from Discovery's pivotal, multinational SELECT study demonstrate that Surfaxin is significantly more effective in the prevention of RDS and results in improved survival (continuing through at least one year of life) and other outcomes versus comparator surfactants. The SELECT and STAR (a supportive Phase 3 study) trials, as well as a pooled Phase 3 analysis, have been presented at several international medical meetings and the results from the two studies were published in Pediatrics.

Aerosurf is a precision-engineered, aerosolized SRT administered via nasal continuou
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Major New Review Supports the Broader Potential of CeNeS COMT Inhibitor Discovery Programme
2. Discoverys KL-4 Surfactant Technology Demonstrates Novel Anti-Inflammatory Properties
3. Major Discovery Raises Prospect of Better Patient Care By Improving Platelet Life Span
4. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
5. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
6. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
7. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
8. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
9. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
10. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
11. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
Post Your Comments:
(Date:8/1/2014)... PALO ALTO, Calif. , Aug. 1, 2014 ... today announced a partnership to expand awareness of proper ... the CFChef Shares program. CFChef Shares will run from ... AbbVie,s CFChef program – an online resource for CF ... a healthy diet by submitting recipes to the ...
(Date:8/1/2014)... Mass. , Aug. 1, 2014  NxStage Medical, Inc. ... dialysis products, today announced that Jeffrey H. Burbank , ... Officer, will present at the 34 th Annual Canaccord ... Boston, MA , on Wednesday, August 13 th ... will be made available at http://ir.nxstage.com/ .  ...
(Date:8/1/2014)... Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced ... report its second quarter 2014 financial results on Monday, ... J. Joseph Kim and CFO Peter ... corporate update, and participate in a live Q&A with ... VGX-3100, Inovio,s immune therapy targeting pre-cancers and cancers associated ...
Breaking Medicine Technology:AbbVie and Cystic Fibrosis Research, Inc. (CFRI) Team Up to Raise Awareness of the Nutritional Needs of CF Patients through the CFChef Shares Program 2AbbVie and Cystic Fibrosis Research, Inc. (CFRI) Team Up to Raise Awareness of the Nutritional Needs of CF Patients through the CFChef Shares Program 3NxStage to Present at the 34th Annual Canaccord Genuity Growth Conference 2Inovio Pharmaceuticals to Host Second Quarter 2014 Financial Results Call on August 11, 2014 2Inovio Pharmaceuticals to Host Second Quarter 2014 Financial Results Call on August 11, 2014 3
(Date:8/1/2014)... Gerontological Society of America (GSA) ... field of aging has chosen Madonna Harrington ... PhD, of the University of Luxembourg; and Philipp ... The London School of Economics and Political Science ... Innovative Publication Awards. , These distinguished honors recognize ...
(Date:8/1/2014)... 2014 Lifeinsurancenomedicalexam.info has released a ... for clients who have high cholesterol levels. , ... and qualify for no medical exam life insurance. These ... background medical check-ups. , Since there are no medical ... will qualify in just a few minutes. However, this ...
(Date:8/1/2014)... August 01, 2014 Home Care Assistance ... seniors, is honored to be recognized as a 2014 Best ... given to home care providers who rank in the top ... on monthly satisfaction interviews conducted by Home Care Pulse. , ... home care businesses, the best of the best!” says Home ...
(Date:8/1/2014)... aesthetic injectable procedures have grown in popularity as more ... As Botulinum toxin generally known as BOTOX ... health professionals have emerged to perform procedures utilizing this ... Spinelli, MD from the Division of Plastic Surgery Presbyterian ... from Columbia University in New York have assessed the ...
(Date:8/1/2014)... CapsCanada, a leading provider of ... new K-CAPS® (HPMC capsules) manufacturing facility in Lakeshore, ... last year while experiencing growing global demand for ... “KCAPS® are currently sold in more than 60 ... to other HPMC capsules, K-CAPS® have exceptional appearance ...
Breaking Medicine News(10 mins):Health News:Harrington Meyer, Leist, Hessel, Avendano to receive GSA's 2014 Kalish awards 2Health News:No Exam Life Insurance - Coverage for Clients Who Have High Cholesterol 2Health News:Cincinnati Senior Care Company Receives 2014 Best of Home Care® Employer of Choice Award 2Health News:Plastic surgeons or nurses: Who are the better injectors? 2
... focused on the use of cholesterol-lowering drugs also ... and C-reactive protein levels. C-reactive protein is a ... inflammation in the arteries. One study shows C-reactive ... cardiovascular risk.,Researchers focused on whether the lower low-density ...
... heart's own can, such as raising the heart rate when ... hill but researchers say a pacemaker created by // stem ... shown that genetically engineered heart cells from human embryonic stem ... to a new study. Researchers injected clusters of human beating ...
... body’s immune system and help protect the body against ... shows promising treatment for acute myelogenous leukemia // ... from a patient’s family member. Researchers say this ... cancer of the bone marrow that has become resistant ...
... unexpected structural differences in the brains of cocaine addicts. ... brain structure // of 27 cocaine addicts to that ... ,Results showed the amygdala -- a key structure in ... brain's reward processing system -- is smaller in cocaine ...
... more important factor associated with childhood allergies and asthma than ... to a new study . // ,The study ... a sample of their cord blood serum taken at birth ... showing a sensitization to certain allergens.The children were assessed at ...
... Epilepsy is a disorder caused by abnormal surges in the ... is found to affect more than 2 million people worldwide. ... by just taking medications. // ,Researchers now say that ... effective surgery is compared to drug therapy when treating those ...
Cached Medicine News:
The AIA-600 II has become the new standard in benchtop immunoassay analyzers....
... The ACON PSA Semi-Quantitative Prostate Specific ... Blood/Serum/Plasma) are lateral flow tests in strip ... of Prostate Specific Antigen (PSA). The tests ... ng/mL cut-off values, and all come with ...
... Assess Functional Vision, Quality of Vision ... controls both target illumination and glare ... testing results. Day/Night testing with/without glare ... Standards and all ANSI standards. All ...
... is Recognized as a Valuable Tool ... by Early Eye Disease. Near Test ... 7 in (12.7cm x 17.78cm) Can ... Refractor,Distance Test F.A.C.T. 201: Size ...
Medicine Products: